Last updated: April 21, 2024
Sponsor: University Hospital of Patras
Overall Status: Active - Recruiting
Phase
N/A
Condition
Liver Disease
Digestive System Neoplasms
Liver Cancer
Treatment
Transarterial Radioembolization
Clinical Study ID
NCT06257030
735
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Age >18 yr
- Both sexes eligible for study
- Patients with primary or secondary liver tumors
- Liver dominant disease
- At least one lesion greater than 5.0 cm in maximum diameter
- Life-expectancy > 3 months
- FLR >40% or greater than 500mls
- Must be able to tolerate pre-treatment CT scan , DSA and 99mTc-MAA infusion andimaging with SPECT/CT scan
- Able to schedule and tolerate post-treatment Y90 PET/CT imaging
- Able to tolerate follow-up imaging with dynamic contrast CT liver phase or MRI withliver specific contrast at 3mo, 6mo, 9mo, 1yr, 2.0 yr, and 3.0 years.
Exclusion
Exclusion Criteria:
- Child Pugh > B
- Bilirubin >2 mg/dl
- Albumin<3.0
- Central portal invasion
- Multi-focal bilobar disease
- Disseminated extrahepatic disease
- Lung shunt >20% or a estimated Lung dose > 20 Gy
- Focuses of extra-hepatic liver uptake.
- Patients that cannot tolerate addition follow-up imaging.
Study Design
Total Participants: 100
Treatment Group(s): 1
Primary Treatment: Transarterial Radioembolization
Phase:
Study Start date:
February 05, 2024
Estimated Completion Date:
February 05, 2027
Connect with a study center
University Hospital of Patras
Patra, Achaia 26500
GreeceActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.